Physician profile
Ramon E Rodriguez
NPI 1699832774
$4,075.02
in general payments reported to CMS, 2019-2025
30 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $144 · 2021: $417 · 2022: $568 · 2023: $784 · 2024: $897 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.77 |
| Education | $484.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $913.97 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Endo Pharmaceuticals INC. | $434.98 | 2019-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $421.72 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $324.68 | 2019-2025 | Erleada |
| Tolmar, INC. | $302.02 | 2023-2025 | Eligard |
| Abbvie INC. | $252.66 | 2021-2025 | Lupron Depot |
| Pfizer INC. | $191.09 | 2019-2025 | |
| 180 Medical, INC. | $154.67 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.71 | 2025 | |
| Kyowa Kirin, INC. | $120.22 | 2023 | Nourianz |
| Myovant Sciences INC. | $113.77 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $83.30 | 2021 | |
| Urovant Sciences INC | $69.72 | 2021-2022 | |
| Endo USA, INC. | $65.65 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $64.63 | 2023-2025 | Jelmyto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $58.36 | 2019-2025 | |
| C. R. Bard, INC. & Subsidiaries | $53.10 | 2022-2023 | Bard Urinary Drainage Bag |
| Verity Pharmaceuticals INC. | $42.65 | 2025 | Trelstar |
| Olympus America INC. | $36.24 | 2025 | Itind System |
| Abc Home Medical Supply, INC. | $31.99 | 2025 | |
| Smith+Nephew, INC. | $24.07 | 2019 | |
| Clarus Therapeutics INC. | $23.30 | 2021 | |
| Royal Biologics, INC. | $21.40 | 2020 | |
| Ferring Pharmaceuticals INC. | $20.69 | 2024 | Adstiladrin |
| Neotract INC. | $20.48 | 2020 | |
| Bioprotect Medical, INC. | $20.35 | 2025 | Bioprotect Balloon Implant System |
| Convatec INC. | $18.99 | 2024 | |
| Boston Scientific Corporation | $18.05 | 2024 | Ams 700 |
| Accord Healthcare, INC. | $16.60 | 2022 | |
| Teleflex LLC | $14.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.